Analysts Offer Predictions for ESPR FY2024 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the year. Cantor Fitzgerald has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.27) per share.

A number of other research firms have also recently weighed in on ESPR. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, December 12th. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a report on Wednesday. They set a “neutral” rating and a $4.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.30.

Esperion Therapeutics Trading Up 2.8 %

NASDAQ:ESPR traded up $0.06 on Thursday, hitting $2.22. The company’s stock had a trading volume of 680,053 shares, compared to its average volume of 6,364,525. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The stock has a fifty day moving average of $2.41 and a two-hundred day moving average of $2.22. The firm has a market capitalization of $437.42 million, a P/E ratio of -3.47 and a beta of 1.01.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently bought and sold shares of ESPR. BOKF NA bought a new position in shares of Esperion Therapeutics during the second quarter worth approximately $26,000. Traphagen Investment Advisors LLC acquired a new stake in Esperion Therapeutics during the third quarter worth approximately $27,000. Xponance Inc. bought a new position in Esperion Therapeutics during the 2nd quarter worth $28,000. National Bank of Canada FI raised its holdings in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at $44,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.